No not necessarily but when you are looking at a d

No not necessarily but when you are looking at a drug to determine its effectiveness against HIV you are looking at the good (eg efficacy) and bad (eg mutations) of how it performs in the trials against SOC of a specific regimen. It’s been years since I have looked at LL’s HIV trials, and maybe Ohm can comment, but I don’t think there have been any mutations that appear with LL- not certain.

I was thinking off cuff yesterday that since the inflammation trial isn’t looking at LL on how it performs against HIV (but rather inflammatory biomarkers) but it is being studied in both arms that contain